**South African National Essential Medicines List**

**Budget Impact Analysis**

**Name of STG ERC**

**Component: STG chapter and section**

**Generic name of health technology and relevant indication (e.g. x for treating x)**

**Date**

# EXECUTIVE SUMMARY

|  |
| --- |
| **Medicine:**  **Indication:**  **Research question:**  **Patient population:**  **Level of Care:**  **Prescriber level:**  **Current Standard of Care/ Comparator(s):**  **Methods:**  **Findings:**  **Recommendations:**  **Reviewers:**  **PTC affiliation:**  **Disclosures:**  **Funding support:** |

**NAMES OF REVIEWERS**

**AFFILIATION AND CONFLICT OF INTEREST**

Potential conflict of interest statement included here.

Official form should be completed and sent to EDP prior to undertaking the review:

# INTRODUCTION

Brief description of the following:

* Rationale for why this type of analysis has been selected
* Brief description of the condition, the current care pathway and treatment alternatives already available in the South African public health sector (reference Standard Treatment Guidelines and other Department of Health clinical guidelines, if relevant).
* Identify the main resource use associated with the technology under review and its comparators

# technology under review

|  |  |  |
| --- | --- | --- |
|  | Cost (ZAR) | Source |
| **Acquisition cost** |  |  |
| **Method of administration** |  |  |
| **Dosage** |  |  |
| **Average length of a course of treatment** |  |  |
| **Anticipated average interval between courses of treatments** |  |  |
| **Anticipated number of repeat treatments** |  |  |
| **Dose adjustments** |  |  |

Table adapted from the NICE budget impact analysis template

# Uptake and market share

Provide information to support estimates of market share for the current treatment options and for the technology for the next 5 years (presented for the following scenarios: status quo, rapid adoption of the new technology, and slow adoption of the technology).

Adapt the table below to show how the full eligible population of each year is split across the different treatment options.

**Uptake and market share**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Scenario** | **Treatment** | **Year 1** | **Year 2** | **Year 3** | **Year 4** | **Year 5** |
| Status Quo:  Market share of existing treatment(s) only | Technology | 0.00% | 0,00% | 0,00% | 0,00% | 0,00% |
| Comparator A | % | % | % | % | % |
| Comparator B | % | % | % | % | % |
| Rapid Adoption Scenario | Intervention A | % | % | % | % | % |
| Comparator A | % | % | % | % | % |
| Comparator B | % | % | % | % | % |
| Slow Adoption Scenario | Intervention A | % | % | % | % | % |
| Comparator A | % | % | % | % | % |
| Comparator B | % | % | % | % | % |

# Eligible population

Describe the following:

* whether it is an incident population, prevalent population or both that is anticipated would use the technology
* how many people are eligible for treatment with the technology for the licenced indication and for any subgroups considered for the next 5 years
* details of any assumptions used and describe all steps taken to calculate the eligible population

# Resources

Describe the following:

* Healthcare resource use associated with the technology under review and specify whether this is different to current clinical practice. This may include administration costs, staff costs and costs of monitoring and tests associated with the technology, additional tests or investigations needed etc.
* Adverse events associated with the technology if this is different to current standard of care
* Location or setting of care (that is, primary and/or secondary care/homecare).
* Any concomitant therapies
* Any anticipated savings (or events avoided) associated with the technology
* Details of any assumptions used

Adapt the table below to set out all relevant summary costs for the technology under review and its comparators. All costs should be presented separately with itemised unit costs in the accompanying excel spreadsheet.

**Unit costs for technology and comparator technologies**

|  |  |  |
| --- | --- | --- |
| Cost type | Cost (ZAR) | Unit |
| Technology | | |
| Acquisition cots |  | Per person per course of treatment |
| Health care resource use |  | Per person per year |
| Adverse events |  | Per event (x many per person per year) |
| Events avoided |  | Per person per year |
| Comparator 1 | | |
| Acquisition cots |  | Per person per course of treatment |
| Health care resource use |  | Per person per year |
| Adverse events |  | Per event (x many per person per year) |
| Events avoided |  | Per person per year |
| Comparator 2 | | |
| Acquisition costs |  | Per person per course of treatment |
| Health care resource use |  | Per person per year |
| Adverse events |  | Per event (x many per person per year) |
| Events avoided |  | Per person per year |
| *Add further rows as needed* | | |

Table adapted from the NICE budget impact analysis template

# Estimates of annual budget impact

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Year 1** | **Year 2** | **Year 3** | **Year 4** | **Year 5** |
| **Patient population that will receive the new technology** | **0** | **0** | **0** | **0** | **0** |
| **Status quo implementation scenario** |  |  |  |  |  |
| Pharmaceutical costs |  |  |  |  |  |
| Healthcare resource use costs |  |  |  |  |  |
| Adverse events costs |  |  |  |  |  |
| Other costs/savings not captured elsewhere |  |  |  |  |  |
| *Total cost of current treatment pathway* |  |  |  |  |  |
| **Rapid adoption implementation scenario** |  |  |  |  |  |
| Pharmaceutical costs |  |  |  |  |  |
| Healthcare resource use costs |  |  |  |  |  |
| Adverse events costs |  |  |  |  |  |
| Other costs/savings not captured elsewhere |  |  |  |  |  |
| *Total cost of rapid adoption of technology* |  |  |  |  |  |
| **Slow adoption implementation scenario** |  |  |  |  |  |
| Pharmaceutical costs |  |  |  |  |  |
| Healthcare resource use costs |  |  |  |  |  |
| Adverse events costs |  |  |  |  |  |
| Other costs/savings not captured elsewhere |  |  |  |  |  |
| *Total cost of slow adoption of technology* |  |  |  |  |  |
| **NET BUDGET IMPACT** *(future - current treatment pathway costs)* |  |  |  |  |  |
| **Net pharmaceutical costs** |  |  |  |  |  |
| > In a market with rapid adoption of the new technology |  |  |  |  |  |
| > In a market with slow adoption of the new technology |  |  |  |  |  |
| **Net healthcare resource use costs** |  |  |  |  |  |
| > In a market with rapid adoption of the new technology |  |  |  |  |  |
| > In a market with slow adoption of the new technology |  |  |  |  |  |
| **Net adverse events costs** |  |  |  |  |  |
| > In a market with rapid adoption of the new technology |  |  |  |  |  |
| > In a market with slow adoption of the new technology |  |  |  |  |  |
| **Net costs not captured elsewhere (savings)** |  |  |  |  |  |
| > In a market with rapid adoption of the new technology |  |  |  |  |  |
| > In a market with slow adoption of the new technology |  |  |  |  |  |
| **Net total costs** |  |  |  |  |  |
| > In a market with rapid adoption of the new technology |  |  |  |  |  |
| > In a market with slow adoption of the new technology |  |  |  |  |  |

# Limitations of the budget impact assessment

# REFERENCES

Vancouver style format